Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANRG -- Anergen -- new CEO big chance ? -- Ignore unavailable to you. Want to Upgrade?

To: christopher who wrote (76)	2/11/1998 8:02:00 AM
From: Douglas	Read Replies (1) \| Respond to of 123

Novo Nordisk has a homepage at: novo.dk It seems that this company is aligning their discovery work within three therapeutic areas: Diabetes Care, Women's Health Care and Growth Disorders. Novo mentions Osteoporosis, Infertility, Contraception, Obesity, Diabetes, Hormone Replacement, and Enzymes It would seem like Multiple Sclerosis a degenerative disease of the central nervous system isn't part of their alignment. Time will only tell if they know something negative about AG-284. Do you know when Anergen & Novo started their phase I trial of AG-284? I could only find a reference to its conclusion in the 3rd quarter of 1998.